
Isaac B Hilton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3863131/publications.pdf Version: 2024-02-01



ISAAC R HILTON

#	Article	IF	CITATIONS
1	Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nature Biotechnology, 2015, 33, 510-517.	17.5	1,487
2	CRISPR–Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome. Nature Biotechnology, 2017, 35, 561-568.	17.5	362
3	Editing the epigenome: technologies for programmable transcription and epigenetic modulation. Nature Methods, 2016, 13, 127-137.	19.0	341
4	Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector. Nucleic Acids Research, 2014, 42, e147-e147.	14.5	301
5	Engineering the next generation of cell-based therapeutics. Nature Reviews Drug Discovery, 2022, 21, 655-675.	46.4	93
6	Enabling functional genomics with genome engineering. Genome Research, 2015, 25, 1442-1455.	5.5	89
7	mTOR Inhibitors Block Kaposi Sarcoma Growth by Inhibiting Essential Autocrine Growth Factors and Tumor Angiogenesis. Cancer Research, 2013, 73, 2235-2246.	0.9	65
8	Distinct p53, p53:LANA, and LANA Complexes in Kaposi's Sarcoma-Associated Herpesvirus Lymphomas. Journal of Virology, 2010, 84, 3898-3908.	3.4	62
9	Transgenic mice for in vivo epigenome editing with CRISPR-based systems. Nature Methods, 2021, 18, 965-974.	19.0	56
10	Single C-to-T substitution using engineered APOBEC3G-nCas9 base editors with minimum genome- and transcriptome-wide off-target effects. Science Advances, 2020, 6, eaba1773.	10.3	55
11	CRISPR/Cas-Based Epigenome Editing: Advances, Applications, and Clinical Utility. Trends in Biotechnology, 2021, 39, 678-691.	9.3	47
12	Programmable human histone phosphorylation and gene activation using a CRISPR/Cas9-based chromatin kinase. Nature Communications, 2021, 12, 896.	12.8	39
13	The Open Chromatin Landscape of Kaposi's Sarcoma-Associated Herpesvirus. Journal of Virology, 2013, 87, 11831-11842.	3.4	38
14	Reversing Post-Infectious Epigenetic-Mediated Immune Suppression. Frontiers in Immunology, 2021, 12, 688132.	4.8	21
15	Quantitative Analysis of the Bidirectional Viral G-Protein-Coupled Receptor and Lytic Latency-Associated Nuclear Antigen Promoter of Kaposi's Sarcoma-Associated Herpesvirus. Journal of Virology, 2012, 86, 9683-9695.	3.4	9
16	Chemical control for CRISPR editing. Nature Chemical Biology, 2017, 13, 2-3.	8.0	3